Sugi Predict

Sugi Predict / Compounds / SCHEMBL7008939

SCHEMBL7008939

SCHEMBL7008939

COc1cc(Br)c2[nH]c(C)cc2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AXL P30530 1/20 0.50
▸ XDH P47989 1/20 0.41
▸ CYP1A1 P04798 4/20 0.39
▸ CYP1B1 Q16678 4/20 0.39
▸ ALDH1A1 P00352 3/20 0.37
▸ PDE3B Q13370 1/20 0.37
▸ PDE3A Q14432 1/20 0.37
▸ MAOA P21397 1/20 0.35
▸ MAOB P27338 1/20 0.35
▸ ALOX5 P09917 4/20 0.34
▸ TTR P02766 3/20 0.34
▸ NQO2 P16083 3/20 0.34
▸ PTGS2 P35354 3/20 0.34
▸ ABL1 P00519 2/20 0.34
▸ ABCB1 P08183 2/20 0.34
▸ BCR P11274 2/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ GAA P10253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14115029 0.82 AXL (0.52) AXLCYP1A1CYP1B1ALDH1A1PDE3B
SCHEMBL17453006 0.79 AXL (0.49) AXLCYP1A1CYP1B1ALDH1A1PDE3B
SCHEMBL21884856 0.79 AXL (0.49) AXLCYP1A1CYP1B1ALDH1A1PDE3B
SCHEMBL7006443 0.76 XDH (0.37) XDHMEN1NPC1RAB9AKMT2A
SCHEMBL21235450 0.74 XDH (0.36) XDHMAOAMAOBGAAHPGD
SCHEMBL38660807 0.73 XDH (0.73) XDHALDH1A1ABL1KDM4ENPC1
SCHEMBL30231485 0.71 GPR84 (0.41) XDHCYP1A1CYP1B1ALOX5TTR
SCHEMBL9739954 0.69 ALDH1A1 (0.37) AXLCYP1A1CYP1B1ALDH1A1PDE3B
SCHEMBL985652 0.69 MEN1 (0.47) AXLCYP1A1CYP1B1ALDH1A1MAOA
SCHEMBL597517 0.68 CA12 (0.50) AXLALDH1A1MAOAMAOBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111989321-B KRAS G12C inhibitors 米拉蒂治疗股份有限公司 2024-05-14 — — CN disclosed
US-20240101553-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2024-03-28 — — US disclosed
US-20230373999-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-11-23 — — US disclosed
US-20230373999-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-11-23 — — US disclosed
US-20230373999-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-11-23 — — US disclosed
CN-109843856-B KRAS G12C inhibitors 米拉蒂治疗股份有限公司 2023-05-02 — — CN disclosed
EP-3710439-B1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-02-15 — — EP disclosed
EP-3710439-B1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-02-15 — — EP disclosed
US-11267812-B2 KRAS G12C inhibitors Mirati Therapeutics, Inc. (US) 2022-03-08 — — US disclosed
EP-3458445-B1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2021-02-17 — — EP disclosed
US-10689377-B2 KRas G12C inhibitors Mirati Therapeutics, Inc. (US) 2020-06-23 — — US disclosed
US-10633381-B2 KRas G12C inhibitors Mirati Therapeutics, Inc. (US) 2020-04-28 — — US disclosed
US-20190144444-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2019-05-16 — — US disclosed
EP-3458445-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2019-03-27 — — EP disclosed
US-10125134-B2 KRas G12C inhibitors Mirati Therapeutics, Inc. (US) 2018-11-13 — — US disclosed
US-20180072723-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2018-03-15 — — US disclosed
US-20180072723-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2018-03-15 — — US disclosed
WO-2017201161-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2017-11-23 — — WO disclosed
EP-1325011-A2 METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES ELI LILLY AND COMPANY (US) 2003-07-09 — — EP disclosed
WO-2002028861-A2 METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES ELI LILLY AND COMPANY (US) 2002-04-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190144444-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS AXL 4091/4885XDH 4517/4885CYP1A1 3346/4885
US-10633381-B2 KRas G12C inhibitors KRAS, NRAS, HRAS AXL 4091/4885XDH 4517/4885CYP1A1 3346/4885
US-11267812-B2 KRAS G12C inhibitors KRAS, NRAS, HRAS AXL 4091/4885XDH 4517/4885CYP1A1 3346/4885
US-10125134-B2 KRas G12C inhibitors KRAS, NRAS, HRAS AXL 4091/4885XDH 4517/4885CYP1A1 3346/4885
US-10689377-B2 KRas G12C inhibitors KRAS, NRAS, HRAS AXL 4091/4885XDH 4517/4885CYP1A1 3346/4885
US-20240101553-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS AXL 4091/4885XDH 4517/4885CYP1A1 3346/4885
US-20180072723-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS AXL 4091/4885XDH 4517/4885CYP1A1 3346/4885
US-20230373999-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS AXL 4091/4885XDH 4517/4885CYP1A1 3346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.